The WinSanTor Solution

HOPE FOR NEUROPATHY SUFFERERS

Unmet Need

Neuropathy affects nearly 1 in 15 Americans. It is one of the largest unmet medical challenges existing today, with no FDA-approved treatments outside analgesics.

Peripheral Neuropathies

Breakthrough

We are working to treat peripheral neuropathy by reversing and regenerating nerves. Our results validate the discovery of a pathway to augment nerve growth and sensory function.

Our Solution

Drive

Who We Are:
+ Key Opinion Leaders
+ Leading Institutional Stakeholders
+ Proven Management Team
+ World Class Advisors

The Team

Strategy

We are focused on managing global resources to accelerate the development of treatment for patients with peripheral neuropathy.

Pipeline

Meet June

June is an 85-year-old woman who got neuropathy from the radiation treatment for her breast cancer. She has lost feeling in her feet and experiences numbing in her calves. Like so many others, she now has to use a walker.

Read More Patient Testimonials

Recent News

WinSanTor · 4 days ago
@WinSanTor
This month, Mental Health Awareness Month, we are raising awareness about the mental impact of peripheral neuropathy - and how to manage it.
https://t.co/tH5izNFEpR

#MentalHealthAwarenessMonth #MentalHealthMonth #WinSanTor #PeripheralNeuropathy #blogpost
View on Twitter
0
2
WinSanTor · 1 week ago
@WinSanTor
May 1-8 was National Neuropathy Awareness Week. Help us call attention to this common yet neglected condition.

#PeripheralNeuropathy #WinSanTor #Infographic #HealthAwareness #NationalNeuropathyAwarenessWeek https://t.co/lZVxZDTikW
View on Twitter
2
5
WinSanTor · 3 weeks ago
@WinSanTor
May 1-8 is National Neuropathy Awareness Week. Help us call attention to this common yet neglected condition: https://t.co/GwE8QraFqd #peripheralneuropathy @FoundationforPN
View on Twitter
0
1

Investors

WinSanTor Inc. is a private biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. WinSanTor recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.

Investor Information

Conquering Diabetic Neuropathy

Drs. Calcutt and Fernyhough on WST-057 and on treating and preventing nerve damage caused by diabetes.